Table 5.
Prevalence n (%) [n (%)] of ID testing among anaemic patients by CKD stage
| Total | CKD Stages 1–2 | CKD Stage 3 | CKD Stages 4–5 | P-value | |
|---|---|---|---|---|---|
| na (%) | (n = 436) | (n = 133) | (n = 171) | (n = 132) | |
| Hb < 10 g/dL | 19 (4.4) | 2 (1.5) | 6 (3.5) | 11 (8.3) | 0.023 |
| Hb < 11 g/dL | 59 (13.5) | 6 (4.5) | 13 (7.6) | 40 (30.3) | <0.001 |
| Hb < 12 g/dL | 95 (21.8) | 13 (9.8) | 22 (12.9) | 60 (45.5) | <0.001 |
| WHO definitionb | 113 (25.9) | 17 (12.8) | 29 (17.0) | 67 (50.8) | <0.001 |
| Totalc | 176 (37.9) | 41 (28.5) | 51 (28.5) | 84 (59.6) | <0.001 |
a
Number of patients with available Hb and eGFR.
b
WHO criteria: Hb <13 g/dL for men and <12 g/dL for women.
c
Irrespective of anaemia status; eGFR was available on a total of 464 patients.